EN DE
Watch Varex Imaging Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Varex Imaging Corp (VREX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Varex Imaging Corp stock $3.96, price $18.44, that is 78.5% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

VI Varex Imaging Corp logo Some data Nov 5, 2026

Varex Imaging Corp

VREX · US
Solid, but very expensive

Our calculation puts a fair price 79% below what the stock costs today.

Quality 50/100
Mixed Growth (revenue 5y +2.7 %/yr in USD)
Thin margins · 2.6% net margin (TTM) · excl. goodwill write-downs +13.4%
Moderate debt
Insiders sold $2.5M (6M)
Some data
Fair value $3.96 · Strongly overvalued (−78.5%)
Negative free cash flow over the last twelve months
Trails peers (5/14)
Narrow moat 31/100 · thin data
Watch Varex Imaging Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$32.41 $6.88 Fair Value $3.96 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range $6.88 – $32.41 · fair‑value band $2.19 – $5.93 · the $18.44 price screens above the $3.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.

Follow Varex Imaging in your weekly email

Every Wednesday you see whether Varex Imaging is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. It operates through two segments, Medical and Industrial.

Show moreShow less

The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers.

This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses.

The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications.

It sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, the Middle East, India, Africa, Asia, and Australia.

The company was incorporated in 2016 and is headquartered in Salt Lake City, Utah.

Stock analysis

Varex Imaging Corp (VREX) currently trades at $18.44, while our model-based Fair Value estimate is $3.96, 79% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $5.02 per share, and 0 of the 6 models we run sit above the $18.44 price.

Bear case: the DCF Models group reads lowest at $3.96, and 6 of the 6 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $2.19 (bear) to $5.93 (bull), the price of $18.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Varex Imaging Corp reported revenue of $845M in FY2025 versus $818M in FY2021, a compound +0.8%/yr. Reported net income was −$70.3M in FY2025.

Key figures

Market cap $786M Small · P/E ratio 34.8 · P/S ratio 0.91 · EPS (TTM) $0.5300 · Net margin 2.6% · Return on equity 4.6% · Return on assets (EBIT) 4.0% (5-year average) · Operating margin 10.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −79%, VREX screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($0.1600 to $7.02). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $2.19 Fair Value $3.96 Bull $5.93
Price $18.44 · Downside -78.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.5300 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $4.18 $7.01 $10.69 79
Growth DCF $4.38 $7.02 $10.28 78
5Y Revenue Exit $0.9500 $2.81 $5.09 68
All 7 models by family
DCF Models
FCF DCF $4.18 $7.01 $10.69 79
5Y Revenue Exit $0.9500 $2.81 $5.09 68
10Y Revenue Exit $2.19 $3.96 $5.93 66
Multiples
EV/Revenue n/a n/a $1.43 50
Asset-Based
NCAV (Graham) $0.1100 $0.1600 $0.2100 54
Growth DCF
Growth DCF $4.38 $7.02 $10.28 78
Rev-Margin DCF $0.9500 $3.01 $5.32 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 46
Are margins and returns getting better?
Cashflow 23
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 35
How calm the share price moves, does not count
Price momentum 82
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 97
Distance to the 52-week high, does not count
New shares 76
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $2.5M and none bought.

  • SaleJay K. KunkelDirector2× since Mar 20, 2026: 12,631 shares, avg. $15.86$200,317Sep 14, 2026
  • SaleShubham MaheshwariChief Financial Officer130,000 shares at $18.46$2.4MSep 11, 2026

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 49/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Start year 2020 (pandemic). Over 10 years: +2.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4.6% (2020) → −3.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.1%
Yearly sales growth analysts expect, extended to five years.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +29.3% a year for the price and +0.7% for the forecasts.
Forecast 2026 (sales)+3.2%
Forecast 2027 (sales)+3.2%
Projected 2028 (sales)+3.1%
Projected 2029 (sales)+2.9%
Projected 2030 (sales)+2.8%

VREX screens overvalued: fair value 79% below the price. Compare with Abbott Laboratories, →

Compare Varex Imaging Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −78.5% · Bottom 25%
Profitability
Return on equity (12 months) 4.6% · Above median
Return on assets −6.4% · Below median
Net margin (12 months) 2.6% · Below median
Operating margin (12 months) 10.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 3.7% · Below median
Balance sheet
Debt / equity 0.77× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 34.8× · Pricier than median
P/B 1.66× · Cheaper than median
P/S (12 months) 0.91× · Cheapest 25%
Price / free cash flow (fiscal year) 41.8× · Pricier than median
EV/EBITDA 10.1× · Cheaper than median
PEG 6.30× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)19 · sector 35
PAST (return on equity)18 · sector 17
HEALTH (low debt)61 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs VREX
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs VREX
DexCom, Inc DXCM $79.41 $87.35 +10% vs VREX
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs VREX
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs VREX
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs VREX
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs VREX
Abbott Laboratories, ABT $109.93 $75.28 −32% vs VREX
Medtronic plc MDT $101.80 $65.61 −36% vs VREX
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs VREX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Varex Imaging Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Varex Imaging Corp Fair Value". https://www.fairvalue-calculator.com/stock/VREX

Frequently asked questions

Is Varex Imaging Corp (VREX) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $3.96 versus a price of $18.44, about 79% lower (overvalued).
What is the fair value of VREX?
Our model-based fair value for Varex Imaging Corp is $3.96 (as of Nov 5, 2026), built from audited fundamentals. The current price: $18.44.
What is the quality score of VREX?
Varex Imaging Corp has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Varex Imaging Corp (VREX)?
Our model-based price target is the fair value of $3.96 (as of Nov 5, 2026) from 7 valuation models. Cautious scenario $2.19, optimistic scenario $5.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Varex Imaging Corp stock forecast for 2026?
Our models put fair value at $3.96, about 79% lower versus a price of $18.44 (overvalued). Cautious scenario $2.19, optimistic scenario $5.93. The calculation is refreshed regularly with new filings.
What is the revenue of Varex Imaging Corp (VREX)?
Varex Imaging Corp reported trailing-twelve-month revenue of about $865M (latest available figure, as of Nov 5, 2026).
What growth is priced into Varex Imaging Corp (VREX)?
For today's price to be fair in a discounted-cash-flow model, Varex Imaging Corp would have to grow free cash flow by +32.4 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.7 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of VREX use?
Our models discount Varex Imaging Corp at 11.2 %: a base by market capitalisation (small), damped by beta 0.97, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Varex Imaging Corp that is +32.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Varex Imaging Corp (VREX) delivered so far?
Over the past 5 years revenue at Varex Imaging Corp grew +2.7 % a year. The price currently implies free-cash-flow growth of +32.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Varex Imaging Corp (VREX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Varex Imaging Corp (+32.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Varex Imaging Corp (VREX)?
The free-cash-flow yield on the price is 2.39 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Varex Imaging Corp produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Varex Imaging Corp (VREX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Varex Imaging Corp it is $3.96 per share (as of Nov 5, 2026), against a price of $18.44. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Varex Imaging Corp stock overvalued or undervalued in 2026?
As of Nov 5, 2026, VREX trades above its calculated fair value: price $18.44, fair value $3.96, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VREX?
No. The price is what the market pays today ($18.44); the fair value is what the company's own numbers justify ($3.96). For Varex Imaging Corp the two are $14.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Varex Imaging Corp worth?
The market values Varex Imaging Corp at about $786M (market capitalisation, as of Nov 5, 2026). Per share that is $18.44; our models calculate a fair value of $3.96 per share.
What do the bullish and bearish scenarios say about VREX?
Our models span a range for Varex Imaging Corp: cautious scenario $2.19, base $3.96, optimistic $5.93 per share (as of Nov 5, 2026, price $18.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VREX?
Varex Imaging Corp trades at a price-to-earnings ratio of 34.8 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.96 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2017 to 2023), reported earnings: 34.5. Other multiples: PEG 6.3, P/B 1.7, P/S 0.9, EV/EBITDA 10.1.
What is the PEG ratio of VREX?
The PEG ratio of Varex Imaging Corp is 6.30 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Varex Imaging Corp (VREX)?
Balance-sheet figures for Varex Imaging Corp (as of Nov 5, 2026): return on equity 4.6%, debt of 0.77 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is VREX from its 52-week high?
Varex Imaging Corp trades at $18.44, about 1% below its 52-week high of $18.58 and 98% above the low of $9.32 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.96 is for.
Which stocks are comparable to Varex Imaging Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Varex Imaging Corp stock attractive at the current price?
The data as of Nov 5, 2026: price $18.44, calculated fair value $3.96 (−79%), Quality Score 50/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VREX calculated?
We run Varex Imaging Corp through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $3.96 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Varex Imaging Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Varex Imaging Corp (VREX)?
The closing price on Nov 6, 2026 was $18.44. Our model-based fair value is $3.96, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Varex Imaging Corp right now?
The price sits above even our optimistic bull case ($5.93). The favourable scenario is already priced in. The model range is unusually wide ($2.19 to $5.93). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Varex Imaging Corp

How large is the market capitalisation of Varex Imaging Corp (VREX)?
The market capitalisation of Varex Imaging Corp is $786M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Varex Imaging Corp (VREX)?
The price-to-sales ratio of Varex Imaging Corp is 0.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Varex Imaging Corp (VREX)?
Earnings per share at Varex Imaging Corp are $0.5300 (price ÷ EPS = P/E 34.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Varex Imaging Corp (VREX)?
The net margin of Varex Imaging Corp is 2.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Varex Imaging Corp (VREX)?
The return on equity (ROE) of Varex Imaging Corp is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Varex Imaging Corp (VREX)?
On an EBIT basis the return on assets of Varex Imaging Corp is 4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Varex Imaging Corp (VREX)?
The operating margin of Varex Imaging Corp is 10.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Varex Imaging Corp (VREX)?
Revenue at Varex Imaging Corp is growing +3.7% versus a year earlier (3y avg −0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Varex Imaging Corp (VREX)?
Earnings per share at Varex Imaging Corp are growing +453% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Varex Imaging Corp (VREX) carry?
The net debt of Varex Imaging Corp is $257M (fiscal year 2025, ≈ 13.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Varex Imaging Corp in the live analysis

One click puts Varex Imaging Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.